Fractyl Health Inc (GUTS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.70+1.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GUTS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -23.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
GUTS — litigation filed
Dated 2026-07-15
Other Events. On July 15, 2026, the Company reported one-year data from its REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study evaluating Revita for weight maintenance following GLP-1 drug discontinuation. Key One-Year Findings • Dose-dependent durability confirmed at one year: In the full modified intention-to-treat (mITT) population (N=45), a single Revita procedure reduced weight regain by approximately 40% versus sham at one year (least-squares mean weight regain of 7.8% versus 13…
Why it matters: This data is key to see how well Revita helps with weight after GLP-1 therapy.
Supportive ifTopline six-month data from the REMAIN-1 Pivotal Cohort will come in early Q4 2026.
Worry ifThe data shows no real weight maintenance benefit compared to the sham treatment.
Why it matters: If the submission is successful, Revita could be sold. This would affect future revenue and market position.
Supportive ifThe company submits the FDA De Novo application by late Q4 2026.
Worry ifThe company delays or cancels the FDA De Novo submission.
Why it matters: This data will show how well Revita works in real life after GLP-1 therapy.
Supportive ifOne-year data from the REVEAL-1 Cohort is reported in Q2 2026.
Worry ifThe data shows much lower weight maintenance than earlier findings.
Why it matters: This data will show how Revita helps keep weight off after stopping GLP-1.
Supportive ifOne-year data from the REMAIN-1 Midpoint Cohort will be reported in Q3 2026.
Worry ifThe data shows lower weight maintenance rates than earlier reports from the Midpoint Cohort.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$367 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $715 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,343 loss on $10,000 · 83.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Following rules is important for keeping Fractyl's listing. Not following them could hurt investor trust.
Worry ifManagement says they fixed the Nasdaq compliance problems.
Less concerning ifManagement says there is still non-compliance or more actions are needed.
Why it matters: Earnings results will show financial health and progress in operations.
Watch forEarnings report shows revenue growth and positive guidance.
Also watch forEarnings report shows revenue drop or bad guidance.
Why it matters: This data will show how well Revita maintains weight loss after GLP-1 therapy stops. Positive results could support Revita's market potential.
Supportive ifThe latest six-month data from the REMAIN-1 study shows weight maintenance over 50%.
Worry ifData shows weight maintenance under 50%. This means Revita is less effective.
Why it matters: Maintaining cash is vital for funding ongoing clinical trials and operations. A strong cash position supports growth.
Supportive ifManagement says cash runway lasts until early 2027 without big cash loss.
Worry ifManagement says cash runway is shorter than expected. This raises funding concerns.
Why it matters: This data will show how well Revita works long-term. Good results could boost its market position.
Supportive ifData from one year shows that over 50% of Revita patients kept off weight.
Worry ifData shows big weight regain after one year. This raises doubts about Revita's long-term effectiveness.